You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Aurobindo Pharma reported Q2 FY27 revenue of 10,263 crores, up 24% year-on-year, and operating EBITDA of 2,156 crores, up 28%. Management reiterated FY27 guidance for double-digit revenue growth, EBITDA margins north of 21% and absolute EBITDA in excess of 8,000 crore.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XNSE:AUROPHARMA | +1.3% | +8.7% | +24.6% | +8.4% | +54.1% |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-11-11 | 7.00 INR |
| 2025-08-08 | 4.00 INR |
| 2024-02-20 | 1.50 INR |
| 2023-11-20 | 3.00 INR |
| 2023-02-17 | 3.00 INR |
| 2022-06-06 | 4.50 INR |
| 2022-02-18 | 1.50 INR |
| 2021-11-17 | 1.50 INR |
| 2021-08-27 | 1.50 INR |
| 2021-02-22 | 1.50 INR |
| 2020-11-23 | 1.25 INR |
| 2020-08-21 | 1.25 INR |
| 2020-02-17 | 1.75 INR |
| 2019-11-21 | 1.25 INR |
| 2019-02-15 | 1.25 INR |
| 2018-11-20 | 1.25 INR |
| 2018-02-20 | 1.00 INR |
| 2017-11-21 | 1.50 INR |
| 2016-11-24 | 1.25 INR |
| 2016-06-09 | 0.70 INR |
No upcoming investor events are listed for this company yet.
